Assistant Professor @USFHealth, Cardiovascular Scientist, #Cardiometabolic Disease, #HeartFailure @ECI_ISHR https://xitter.cf/t.co/0hfSNN8buc
Joined July 2023
- Tweets146
- Following187
- Followers101
- Likes191
Sharp Laboratory retweeted
Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction academic.oup.com/eurheartj/a…
Check out the latest research from @LeferLab
Sharp Laboratory retweeted
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
Sharp Laboratory retweeted
Still in Milan 🇮🇹 and bringing the science! 🧪🔥Today, Dr. Cristina Rondinone presented our latest results at #EASD2026:🧬A novel unimolecular tetra-agonist targeting GLP-1, GIP, amylin & calcitonin receptors shows superior weight loss vs. tirzepatide or CagriSema in obese rats🐀
Sharp Laboratory retweeted
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.
NIH likely to award fewer grants as it races to spend 2026 budget | Science | AAAS science.org/content/article/…
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026) | Circulation ahajournals.org/doi/10.1161/…
Sharp Laboratory retweeted
The suppressed report that concluded there is no protective or safe level of alcohol consumption, now published. It was commissioned by US Congress
Report jsad.com/doi/10.15288/jsad.2…
Editorial jsad.com/doi/epdf/10.15288/j…
"Despite the study’s adherence to its mandate, its findings were sidelined.”
Sharp Laboratory retweeted
In today's @TheLancet there are 3 papers on cardiometabolic disease: biology, epidemiology, prevention/treatment.
The sobering and all to common story from womb to tomb conveyed in this graphic
thelancet.com/journals/lance…
thelancet.com/journals/lance…
thelancet.com/journals/lance…
Sharp Laboratory retweeted
I'm going through the retatrutide phase 3 data, and the cardiometabolic numbers are more interesting than the weight loss:
- 24.1 cm off the waist on 12mg (9.5 inches)
- significant drops in systolic blood pressure
- triglycerides down
- non-HDL cholesterol down
- hsCRP down (a key marker of inflammation)
I'm giving it a few years before people realize GLP-1s are more than just weight loss drugs.
unavailable
Reta is the next breakthrough. Synergy btw GCGR agonist and anti-obesity effects of single/double-G is profound. Reta in Ms/Rt obese HFpEF models is promising! Differentially regulating PPAR in an organ specific manner. Reta > PPAR quintuple pan-agonism.
Sharp Laboratory retweeted
Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss.
gift link nytimes.com/2026/05/21/scien…
Reta is the next breakthrough. Synergy btw GCGR agonist amplifies the anti-obesity effects of single/double-G. Reta in Ms/Rt obese HFpEF models is wow! Differentially regulating PPAR in an organ specific manner. Reta>PPAR quintuple pan-agonism. Reta metabolic flexibility king.
Sharp Laboratory retweeted
Impressive TRIUMPH-1 #weightloss data for retatrutide investor.lilly.com/news-rele…
Sharp Laboratory retweeted
In SURPASS CVOT tirzepatide was associated with a reduced risk of major kidney events driven by a reduction in new-onset macroalbuminuria in PPL with low-to-moderate-risk CKD #T2D and slowed decline in kidney function in high-risk chronic kidney disease. thelancet.com/journals/landi…
Sharp Laboratory retweeted
In people with HFpEF (heart failure with preserved ejection fraction) and severe obesity, there is a heart muscle cell defect with sarcomere hyper-phosphorylation. Besides weight loss, sarcomere enhancers (not yet studied) may help.
@ScienceMagazine
science.org/doi/10.1126/scie…
Sharp Laboratory retweeted
The rapidly evolving landscape of incretin-based therapies, including GLP1 agonists, necessitates rethinking trial design. Authors present challenges of placebo-controlled trials & potential ways to limit placebo exposure ahajrnls.org/4t0TrPa
Sharp Laboratory retweeted
Multi-organ physiologic deficits during exercise and their metabolic signatures predict incident HFpEF and HF outcomes ahajrnls.org/41k5Hy2
Sharp Laboratory retweeted
Everyone's talking about retatrutide for weight loss (28.7%). Almost nobody's talking about what it does to your liver.
More than 80% reduction in liver fat. Over 90% normalization rates. In a body composition substudy from the Phase 3 program.
100 million Americans have fatty liver disease. Most don't know it. There's no FDA-approved treatment for it besides "lose weight and hope."
Retatrutide's glucagon receptor activation appears to directly target hepatic fat metabolism not just as a side effect of weight loss, but as a primary mechanism.
This isn't a weight loss drug that happens to help your liver. It might be a liver drug that happens to cause weight loss.
Phase 3 weight loss data drops first half of 2026.
Watch this space.
Sharp Laboratory retweeted
Proposed Multidisciplinary Transition Protocol For Patients Undergoing Treatment Using GLP-1RA
dom-pubs.onlinelibrary.wiley…
@DrNadolsky @NutritionMadeS3 @drmatthewnagra @BevTchangMD @MichaelAlbertMD
